Method of treatment and pharmaceutical composition
US6395728B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2001 |
| Grant date | May 28, 2002 |
| Priority date | — |
| Expiry date | Jan 9, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/41
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, myocardial infarction and its sequelae, supraventricular and ventricular arrhythmias, atrial fibrillation or atrial flutter, atherosclerosis, angina (whether stable or ustable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetessecondary aldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and pulmonary hypertension, renal failure conditions, such as diabetic nephropathy,glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), and stroke, comprising administering a therapeutically effective amount of combination of (i) the AT1-antagonists valsartan or a pharmaceutically acceptable salt thereof and (ii) a Calcium channel blocker or a pha…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.